Whilst the US Food and Drug Administration (FDA) has approved five drug therapies to treat obesity (orlistat, phentermine/topiramate, lorcaserin, naltrexone/bupropion, liraglutide), the European Medicines Agency (EMA) has approved only three drug therapies (orlistat, bupropion/naltrexone and liraglutide) [8] at the time of writing
That depends entirely on reconstitution, since 120 mg is the dry vial content, not a dose
doi:10.1016/j.bbrc.2012.08.072 81
Side effects were not worse in a major way in that small study, but that does not mean it is right for everyone
The body of this article is where you find the verification context - what's confirmed on the official site, what the brand claims, what's not independently verified, and what you should ask before enrolling